Recent efforts for developing effective Alzheimer drugs haven’t been successful. Yet, Merck (NYSE:MRK) hopes to do something different with its BACE Inhibitor, MK-8931. The company presented phase 1 clinical trial data in July, which suggested that the drug did reasonably well in reducing amyloid β, and may offer an opportunity to further understand the role BACE1 inhibition plays in the underlying pathology of Alzheimer’s disease. 
The company is expected to come up with phase 2 clinical trial results by the end of the year. But the odds are against the drug as Eli Lily had a failure with a drug that works with similar mechanism. What this essentially implies is that while the market may not be expecting too much from the phase 2 results, a positive surprise can result in meaningful jump in the stock. This is evident from the surge in Incyte’s market value after it announced positive pancreatic cancer data. However, the chances for Merck are slim.
Merck has been struggling for the past few quarters due to the loss of exclusivity of certain key drugs including Singulair, competition from generics and the negative impact of currency movements. To revive its growth, the company is banking on its research in areas like diabetes, cancer immunotherapy and neuroscience. Merck believes that its anti-PD-1 therapy for oncology and ACE inhibitor for Alzheimer’s disease have the capability to change the course of medication, and if successful, can lift its growth outlook.
- Key Trends To Watch Out For Merck This Year
- Why We Are Bullish On Merck
- How Much Revenue Can Merck’s Cancer Drug Keytruda Add In 2020?
- Why Merck’s Cancer Drug Keytruda Can Be Key To Its Long Term Growth?
- Considering The EU Launch Of Biosimilar For Remicade, Merck’s 2nd Largest Drug, Does The Company Face Meaningful EPS Decline In 2016?
- How Much Revenues Can Merck’s Phase 3 Pipeline Add By 2020?
Brief Overview Of Global Alzheimer Market
The research firm BCC Research expects the global Alzheimer’s disease market to grow from an estimated $8 billion in 2009 and to $9.6 billion by 2014, growing at a compound annual growth rate of 3.7%.  Within this market, diagnostics and biomarkers are expected to grow rapidly at a compound annual growth rate (CAGR) of 20%. The sales from this segment stood at $1.2 billion in 2009, and are likely to touch $2.9 billion by 2014, thus constituting roughly 30% of the overall market.  In addition to this, the imaging sector will grow at a CAGR of 19%.  This suggests that most of the growth is likely to come from diagnostics and imaging where Merck has no presence.
Source: BCC Research
Our price estimate for Merck stands at $51.60, implying a premium of about 10% to the market price.Notes: